Back

Cambium Bio secures A$10.85 million for Phase 3 dry-eye trial

Verifying
  • Cambium Bio secured funding to initiate CAMOMILE-2, its pivotal Phase 3 trial of Elate Ocular.
  • A$10.85 million comprises an A$7.1 million placement and an A$3.75 million secured facility.
  • Cambium Bio targets late-2027 data and a 2028 BLA filing, conditional on trial endpoints.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.